PL3076985T3 - Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłości - Google Patents
Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłościInfo
- Publication number
- PL3076985T3 PL3076985T3 PL14806649.1T PL14806649T PL3076985T3 PL 3076985 T3 PL3076985 T3 PL 3076985T3 PL 14806649 T PL14806649 T PL 14806649T PL 3076985 T3 PL3076985 T3 PL 3076985T3
- Authority
- PL
- Poland
- Prior art keywords
- overexpression
- obesity
- treatment
- composition containing
- containing probiotics
- Prior art date
Links
- 102100034663 Caseinolytic peptidase B protein homolog Human genes 0.000 title 1
- 101000946436 Homo sapiens Caseinolytic peptidase B protein homolog Proteins 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 230000002018 overexpression Effects 0.000 title 1
- 239000006041 probiotic Substances 0.000 title 1
- 235000018291 probiotics Nutrition 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/02—Nutritional disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306673 | 2013-12-05 | ||
| EP14306552 | 2014-10-02 | ||
| PCT/EP2014/076611 WO2015082633A1 (en) | 2013-12-05 | 2014-12-04 | Bacterial influence on regulation of appetite via clpb protein mimicry of alpha-msh |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3076985T3 true PL3076985T3 (pl) | 2024-12-16 |
Family
ID=52007031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14806649.1T PL3076985T3 (pl) | 2013-12-05 | 2014-12-04 | Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłości |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160313348A1 (pl) |
| EP (1) | EP3076985B1 (pl) |
| JP (2) | JP2017503768A (pl) |
| KR (1) | KR102332078B1 (pl) |
| CN (1) | CN106061491B (pl) |
| CA (1) | CA2932488A1 (pl) |
| ES (1) | ES2994101T3 (pl) |
| HR (1) | HRP20241279T1 (pl) |
| PL (1) | PL3076985T3 (pl) |
| WO (1) | WO2015082633A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016193829A1 (en) * | 2015-06-05 | 2016-12-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. |
| RU2717018C2 (ru) * | 2014-10-02 | 2020-03-17 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Фармацевтические и пищевые композиции для индукции насыщения и продления чувства сытости у нуждающихся в этом субъектов |
| DK3439684T3 (da) * | 2016-04-05 | 2020-08-03 | Inserm (Institut National De La Santé Et De La Rech Médicale) | Hafnia alvei-baserede farmaceutiske og fødevaresammensætninger til induktion af mæthed og forlængelse af mæthedsfølelse |
| EP3385276A1 (en) * | 2017-04-03 | 2018-10-10 | Targedys | Proteins derived from clpb and uses thereof |
| EP3384922A1 (en) * | 2017-04-03 | 2018-10-10 | Targedys | Brassicaceae protein extract and uses thereof |
| WO2020223609A1 (en) * | 2019-05-01 | 2020-11-05 | New York University | Methods and compositions for sensitizing cancer cells to drug-induced apoptosis |
| EP4426325A1 (en) | 2021-11-03 | 2024-09-11 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Oxytocin-mimetic compositions and uses thereof |
| EP4176890A1 (en) | 2021-11-03 | 2023-05-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Oxytocin-mimetic compositions and uses thereof |
| KR102973977B1 (ko) * | 2021-11-26 | 2026-06-09 | 충남대학교산학협력단 | 알파-멜라노사이트 자극 호르몬의 펩티드 변이체 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997003359A1 (en) | 1995-07-07 | 1997-01-30 | Oravax, Inc. | Helicobacter clpb |
| MX2008009726A (es) | 2006-01-27 | 2009-03-05 | Danisco | Uso de microorganismos probioticos para el tratamiento y prevencion de la obesidad y trastornos relacionados. |
| EP2053122A1 (en) * | 2007-10-23 | 2009-04-29 | Nestec S.A. | Stress tolerant bifidobacteria |
| WO2012011174A1 (ja) * | 2010-07-22 | 2012-01-26 | ビオフェルミン製薬株式会社 | 脂質代謝改善剤、脂質代謝改善作用増強剤、抗肥満剤及び抗肥満作用増強剤 |
| CN105979957A (zh) * | 2013-12-05 | 2016-09-28 | 国家医疗保健研究所 | 细菌通过模拟α-MSH的CLPB蛋白对宿主进食与情绪的影响 |
-
2014
- 2014-12-04 PL PL14806649.1T patent/PL3076985T3/pl unknown
- 2014-12-04 JP JP2016536831A patent/JP2017503768A/ja active Pending
- 2014-12-04 HR HRP20241279TT patent/HRP20241279T1/hr unknown
- 2014-12-04 EP EP14806649.1A patent/EP3076985B1/en active Active
- 2014-12-04 CA CA2932488A patent/CA2932488A1/en not_active Abandoned
- 2014-12-04 ES ES14806649T patent/ES2994101T3/es active Active
- 2014-12-04 CN CN201480066463.6A patent/CN106061491B/zh active Active
- 2014-12-04 US US15/101,452 patent/US20160313348A1/en not_active Abandoned
- 2014-12-04 KR KR1020167017273A patent/KR102332078B1/ko active Active
- 2014-12-04 WO PCT/EP2014/076611 patent/WO2015082633A1/en not_active Ceased
-
2019
- 2019-02-06 JP JP2019019913A patent/JP6876732B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106061491B (zh) | 2021-01-08 |
| EP3076985A1 (en) | 2016-10-12 |
| WO2015082633A1 (en) | 2015-06-11 |
| JP2019089815A (ja) | 2019-06-13 |
| CN106061491A (zh) | 2016-10-26 |
| US20160313348A1 (en) | 2016-10-27 |
| KR20160101944A (ko) | 2016-08-26 |
| ES2994101T3 (en) | 2025-01-17 |
| JP2017503768A (ja) | 2017-02-02 |
| EP3076985B1 (en) | 2024-07-24 |
| KR102332078B1 (ko) | 2021-11-26 |
| CA2932488A1 (en) | 2015-06-11 |
| HRP20241279T1 (hr) | 2024-12-06 |
| EP3076985C0 (en) | 2024-07-24 |
| JP6876732B2 (ja) | 2021-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276106A (en) | Garp-binding proteins and their uses | |
| GB2516335B (en) | The use of phytocannabinoids in the treatment of ovarian carcinoma | |
| PL3542798T3 (pl) | Aceklidyna do zastosowania w leczeniu starczowzroczności | |
| PT2991637T (pt) | Fenfluramina para utilização no tratamento do síndrome de dravet | |
| PL3489261T3 (pl) | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu | |
| SG11201601119XA (en) | Survival benefit in patients with solid tumors with elevated c-reactive protein levels | |
| GB201310909D0 (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| IL242483B (en) | Preparations containing omomyc and their use for cancer treatment | |
| SG11201509782TA (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
| PL3044229T3 (pl) | Peptydy do zastosowania w leczeniu zapalenia błony śluzowej jamy ustnej | |
| EP3076985C0 (en) | COMPOSITION COMPRISING PROBIOTICS CAPABLE OF OVEREXPRESSING CLPB PROTEIN FOR USE IN THE TREATMENT OF OBESITY | |
| SG11201510150VA (en) | Immunotherapy composition and use thereof | |
| PL2910131T3 (pl) | Kompozycja przeciwdziałająca zmęczeniu i jej zastosowanie | |
| IL241418A0 (en) | Improved methods of use for recombinant human secretoglobins | |
| ZA201508050B (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| PL3074033T3 (pl) | Związki do leczenia otyłości i sposoby ich zastosowania | |
| PL2943215T3 (pl) | Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu | |
| SG11201601263WA (en) | Recombinant microorganisms and methods of use thereof | |
| GB201314623D0 (en) | Novel mucinase for use in therapy or prophylaxis |